Search

Distress, confusion, and anger are common responses to COVID-19. Statistics Canada created the Canadian Perspectives Survey Series (CPSS) to understand social issues and effects of COVID-19 on the Canadian labour force (LF). The evaluation of the health and health-related behaviours were done through surveys collected between April and July. Features are composed of 4600 participants and 62 questions, which include the General Anxiety Disorder (GAD)-7 questionnaire. This work proposes the use of CPSS2 survey data characteristics to identify the level of anxiety within the Canadian population during early stages of COVID-19 and is validated with the use of GAD-7 questionnaire. Minimum redundancy maximum relevance (mRMR) is applied to select the top 20 features to represent user anxiety. During classification, decision tree (DT) and support vector machine (SVM) are used to test the separation of anxiety severity. Hierarchical classification was used which separated the anxiety severity labels into different test sets and classified accordingly. We employ SVM for binary classification with 10-fold cross validation to separate the labels of Minimal and Severe anxiety to achieve an overall accuracy of 94.77±0.05%. After analysis, a subset of the reduced feature set can be represented as pseudo passive (PP) data, which are passive sensors that can augment qualitative data. The accurate classification provides proxy on what gives rise to anxiety, as well as the ability to provide early interventions. Future works can implement passive sensors to augment PP data and further understand why people cope this way.

Objectives: There is a general consensus among physicians that the present management of chronic prostatitis is dismal. We undertook a survey of Canadian primary care physicians (PCPs) and urologists to determine the degree and source of frustration and to analyze present practice patterns in this disease., Methods: Five thousand PCPs and all 545 Canadian urologists were asked to complete a comprehensive computer-assisted telephone survey that explored practice characteristics, attitudes, and diagnostic and treatment strategies in the management of prostatitis. Randomization of attribute banks, adherence to questionnaire routing, validation by on-site monitoring, and possible bias were addressed., Results: Completed interviews were obtained from 10% of PCPs and 28% of urologists. PCPs see on average 3.5 (median 2) patients with prostatitis per month and urologists see on average 21.8 (median 11) patients with prostatitis per month. All physicians experience significantly more frustration in treating prostatitis than they do in treating patients with benign prostatic hyperplasia (BPH) and prostate cancer, and they perceive that prostatitis affects patients' quality of life significantly more than BPH and almost as much as prostate cancer. The degree of frustration and unhappiness in dealing with prostatitis is driven by a lack of confidence and comfort in their ability to accurately diagnose and subsequently rationalize treatment. Most PCPs and urologists continue to employ steps in addition to history and physical examination to establish a diagnosis but only a few PCPs and a third of urologists use specific lower urinary tract cultures. Physicians tend to use trimethoprim or trimethoprim-sulfamethoxazole (TMP-SMX) or a fluoroquinolone as their usual first line therapy for chronic prostatitis. The most commonly used therapeutic strategy (40%) for chronic prostatitis was TMP-SMX as first line therapy and a fluoroquinolone as second line therapy., Conclusions: There is widespread frustration, discomfort, and lack of confidence in both PCPs' and urologists' perceived ability to manage prostatitis. Physicians have expressed a desire for a better understanding of this disease, simpler and clearer diagnostic guidelines, and more rational treatment strategies.